Literature DB >> 16134258

Field research in humanitarian medical programmes. Treatment of a cohort of tuberculosis patients using the Manyatta regimen in a conflict zone in South Sudan.

Kees Keus1, Stan Houston, Yosef Melaku, Simon Burling.   

Abstract

This is a descriptive report of a pilot project of tuberculosis (TB) treatment in a conflict zone. A TB programme was implemented by Médecins Sans Frontières(MSF)-Holland in a semi-nomadic population in a very insecure and underdeveloped area of Upper Nile province in Southern Sudan. Outcome measures were operational feasibility, default rate, and sputum smear conversion at 4 months. A cohort of TB patients was admitted over a 10-week period (July-September 2001). Adherence strategy, project implementation, and and contingency planning were adapted to local conditions. The treatment regimen (4 HRZE [4-month daily supervised regimen] followed by 3EH or 3TH [3-month unsupervised regimen]: isoniazid (H), rifampicin (R), pyrazinamide (Z), ethambutol (E) and thiacetazone (T)) was a variant on the Manyatta regimen developed for semi-nomads in Kenya. Of 163 patients, 84 (52%) were children aged < 15 years. Lymph node TB comprised 34% and spinal TB 15% of all patients. Among adults, 41% had smear-positive pulmonary disease. Only 1 patient (0.6%) defaulted. All sputum smear-positive patients who completed 4 months of therapy converted to smear-negative, although 2 were subsequently found to have relapsed. TB in complex emergency situations is an underrecognized priority. Using an approach adapted especially to this setting, TB treatment was successfully implemented with minimal risk of promoting drug resistance, in an unstable setting.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 16134258     DOI: 10.1016/s0035-9203(03)80048-2

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  7 in total

1.  Tuberculosis in complex emergencies.

Authors:  Rudi Coninx
Journal:  Bull World Health Organ       Date:  2007-08       Impact factor: 9.408

2.  Preparation and antitubercular activities in vitro and in vivo of novel Schiff bases of isoniazid.

Authors:  Michael J Hearn; Michael H Cynamon; Michaeline F Chen; Rebecca Coppins; Jessica Davis; Helen Joo-On Kang; Abigail Noble; Becky Tu-Sekine; Marianne S Terrot; Daniella Trombino; Minh Thai; Eleanor R Webster; Rebecca Wilson
Journal:  Eur J Med Chem       Date:  2009-05-21       Impact factor: 6.514

3.  Delivering infectious disease interventions to women and children in conflict settings: a systematic reviefw.

Authors:  Sarah Meteke; Marianne Stefopulos; Daina Als; Michelle Gaffey; Mahdis Kamali; Fahad J Siddiqui; Mariella Munyuzangabo; Reena P Jain; Shailja Shah; Amruta Radhakrishnan; Anushka Ataullahjan; Zulfiqar A Bhutta
Journal:  BMJ Glob Health       Date:  2020-04

4.  Health services uptake among nomadic pastoralist populations in Africa: A systematic review of the literature.

Authors:  Victoria M Gammino; Michael R Diaz; Sarah W Pallas; Abigail R Greenleaf; Molly R Kurnit
Journal:  PLoS Negl Trop Dis       Date:  2020-07-27

5.  Knowledge and perceptions of tuberculosis among patients in a pastoralist community in Kenya: a qualitative study.

Authors:  Grace Wambura Mbuthia; Charles Owour Olungah; Tom Gesora Ondicho
Journal:  Pan Afr Med J       Date:  2018-08-23

6.  Conducting operational research in humanitarian settings: is there a shared path for humanitarians, national public health authorities and academics?

Authors:  Enrica Leresche; Claudia Truppa; Christophe Martin; Ariana Marnicio; Rodolfo Rossi; Carla Zmeter; Hilda Harb; Randa Sami Hamadeh; Jennifer Leaning
Journal:  Confl Health       Date:  2020-05-13       Impact factor: 2.723

Review 7.  Interventions to improve adherence to treatment for paediatric tuberculosis in low- and middle-income countries: a systematic review and meta-analysis.

Authors:  Meaghann S Weaver; Knut Lönnroth; Scott C Howard; Debra L Roter; Catherine G Lam
Journal:  Bull World Health Organ       Date:  2015-06-23       Impact factor: 9.408

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.